CvergenX is the first cancer molecular diagnostics company to develop a companion diagnostic for Radiation Therapy (RT). We will operate as an independent laboratory with testing that provides information for the first time that predicts a tumor’s sensitivity to radiation and assists the radiation oncologist in making more informed therapeutic decisions.